Ion channels and anti-cancer immunity

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1638, 2014, Pages

  Panyi, Gyorgy ^a   Beeton, Christine ^b   Felipe, Antonio ^c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Immunosuppressive network; Ion channel; KCa3.1; Kv1.3; Tumour

Indexed keywords

ANTIGEN; CALCIUM; CYTOLOGY; DISEASE RESISTANCE; DRUG DEVELOPMENT; IMMUNITY; ION; PATHOLOGY; TUMOR;

ION CHANNEL;

CA2+-RELEASE-ACTIVATED CA2+; CALCIUM SIGNALING; CELL PROLIFERATION; CELLULAR IMMUNITY; DRUG ANTAGONISM; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSUPPRESSIVE NETWORK; INNATE IMMUNITY; KCA3.1; KV1.3; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; T LYMPHOCYTE;

CA2+-RELEASE-ACTIVATED CA2+; IMMUNOSUPPRESSIVE NETWORK; ION CHANNEL; KCA3.1; KV1.3; TUMOUR;

CALCIUM SIGNALING; CELL PROLIFERATION; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNITY, INNATE; ION CHANNELS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84893498049     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0106     Document Type: Review

References (87)

1. Barkan D, Green JE, Chambers AF. 2010 Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur. J. Cancer 46, 1181-1188. (doi:10.1016/j.ejca.2010.02.027)
2. Burnet M. 1957 Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br. Med. J. 1, 841-847. (doi:10.1136/bmj.1.5023.841)
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. 2002 Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998. (doi:10.1038/ni1102-991)
4. Chow MT, Moller A, Smyth MJ. 2012 Inflammation and immune surveillance in cancer. Semin. Cancer Biol. 22, 23-32. (doi:10.1016/j.semcancer.2011. 12.004)
5. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. 2013 The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138, 105-115. (doi:10.1111/imm.12036)
6. Finn OJ. 2012 Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 23(Suppl. 8), viii6-9.
7. Cahalan MD, Chandy KG. 2009 The functional network of ion channels in T lymphocytes. Immunol. Rev. 231, 59-87. (doi:10.1111/j.1600-065X.2009.00816.x)
8. Feske S, Skolnik EY, Prakriya M. 2012 Ion channels and transporters in lymphocyte function and immunity. Nat. Rev. Immunol. 12, 532-547. (doi:10.1038/nri3233)
9. + channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression. Curr. Pharm. Des. 12, 2199-2220. (doi:10.2174/1381612067 77585120)
10. Beeton C et al. 2006 Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl Acad. Sci. USA 103, 17 414-17 419. (doi:10.1073/pnas.0605136103)
11. + channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. J. Biol. Chem. 283, 14 559-14 570. (doi:10.1074/jbc.M800637200)
12. Bittner S et al. 2010 Upregulation of K2P5.1 potassium channels in multiple sclerosis. Ann. Neurol. 68, 58-69. (doi:10.1002/ana.22010)
13. Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG. 2006 Orai1 is an essential pore subunit of the CRAC channel. Nature 443, 230-233. (doi:10.1038/nature05122)
14. 2+ stores. Proc. Natl Acad. Sci. USA 90, 6295-6299. (doi:10.1073/pnas.90.13.6295)
15. Schwarz EC, Qu B, Hoth M. 2013 Calcium, cancer and killing: the role of calcium in killing cancer cells by cytotoxic T lymphocytes and natural killer cells. Biochim. Biophys. Acta 1833, 1603-1611. (doi:10.1016/j.bbamcr.2012.11.016)
16. Parekh AB, Putney Jr JW. 2005 Store-operated calcium channels. Physiol. Rev. 85, 757-810. (doi:10.1152/physrev.00057.2003)
17. DeHaven WI, Jones BF, Petranka JG, Smyth JT, Tomita T, Bird GS, Putney Jr JW. 2009 TRPC channels function independently of STIM1 and Orai1. J. Physiol. 587, 2275-2298. (doi:10.1113/jphysiol.2009.170431)
18. Yuan JP, Kim MS, Zeng W, Shin DM, Huang G, Worley PF, Muallem S. 2009 TRPC channels as STIM1-regulated SOCs. Channels 3, 221-225. (doi:10.4161/chan.3.4.9198)
19. Wenning AS, Neblung K, Strauss B, Wolfs MJ, Sappok A, Hoth M, Schwarz EC. 2011 TRP expression pattern and the functional importance of TRPC3 in primary human T-cells. Biochim. Biophys. Acta 1813, 412-423. (doi:10.1016/j.bbamcr. 2010.12.022)
20. Dustin ML, Depoil D. 2011 New insights into the T cell synapse from single molecule techniques. Nat. Rev. Immunol. 11, 672-684. (doi:10.1038/nri3066)
21. Panyi G, Vamosi G, Bacso Z, Bagdany M, Bodnar A, Varga Z, Gaspar R, Matyus L, Damjanovich S. 2004 Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc. Natl Acad. Sci. USA 101, 1285-1290. (doi:10.1073/pnas.0307421100)
22. Lioudyno MI, Kozak JA, Penna A, Safrina O, Zhang SL, Sen D, Roos J, Stauderman KA, Cahalan MD. 2008 Orai1 and STIM1 move to the immunological synapse and are up-regulated during T cell activation. Proc. Natl Acad. Sci. USA 105, 2011-2016. (doi:10.1073/pnas.0706122105)
23. + channel KCa3.1 compartmentalizes in the immunological synapse of human T lymphocytes. Am. J. Physiol. Cell Physiol. 292, C1431-C1439. (doi:10.1152/ajpcell. 00376.2006)
24. Nicolaou SA, Neumeier L, Takimoto K, Lee SM, Duncan HJ, Kant SK, Mongey AB, Filipovich AH, Conforti L. 2010 Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus. Cell Calcium 47, 19-28. (doi:10.1016/j.ceca.2009.11.001)
25. +) accumulation at the immunological synapse: a mathematical model. J. Theor. Biol. 300, 173-182. (doi:10.1016/j.jtbi. 2012.01.018)
26. 1-integrins on the plasma membrane of melanoma cells: effects of cell adherence and channel blockers. J. Gen. Physiol. 120, 29-38. (doi:10.1085/jgp. 20028607)
27. + and opening of voltage-gated potassium channels activate T cell integrin function: physical and functional association between Kv1.3 channels and beta1 integrins. J. Exp. Med. 191, 1167-1176. (doi:10.1084/jem.191.7.1167)
28. Hanada T, Lin L, Chandy KG, Oh SS, Chishti AH. 1997 Human homologue of the Drosophila discs large tumor suppressor binds to p56lck tyrosine kinase and Shaker type Kv1.3 potassium channel in T lymphocytes. J. Biol. Chem. 272, 26 899-26 904.
29. Szilagyi O, Boratko A, Panyi G, Hajdu P. 2013 The role of PSD-95 in the rearrangement of Kv1.3 channels to the immunological synapse. Pflugers Arch. 465, 1341-1353. (doi:10.1007/s00424-013-1256-6)
30. Stinchcombe JC, Bossi G, Booth S, Griffiths GM. 2001 The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 15, 751-761. (doi:10.1016/S1074-7613(01)00234-5)
31. Zweifach A. 2000 Target-cell contact activates a highly selective capacitative calcium entry pathway in cytotoxic T lymphocytes. J. Cell Biol. 148, 603-614. (doi:10.1083/jcb.148.3.603)
32. Franciszkiewicz K, Le Floc'h A, Boutet M, Vergnon I, Schmitt A, Mami-Chouaib F. 2013 CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions. Cancer Res. 73, 617-628. (doi:10.1158/0008-5472.CAN-12-2569)
33. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. 2007 Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689. (doi:10.1038/nri2156)
34. Quintana A et al. 2011 Calcium microdomains at the immunological synapse: how ORAI channels, mitochondria and calcium pumps generate local calcium signals for efficient T-cell activation. EMBO J. 30, 3895-3912. (doi:10.1038/emboj.2011.289)
35. Pores-Fernando AT, Zweifach A. 2009 Calcium influx and signaling in cytotoxic T-lymphocyte lytic granule exocytosis. Immunol. Rev. 231, 160-173. (doi:10.1111/j.1600-065X.2009.00809.x)
36. Maul-Pavicic A et al. 2011 ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. Proc. Natl Acad. Sci. USA 108, 3324-3329. (doi:10.1073/pnas. 1013285108)
37. + T cells. EMBO Mol. Med. 5, 1311-1321. (doi:10.1002/emmm.201302989)
38. Pannasch U, Farber K, Nolte C, Blonski M, Yan Chiu S, Messing A, Kettenmann H. 2006 The potassium channels Kv1.5 and Kv1.3 modulate distinct functions of microglia. Mol. Cell. neurosci. 33, 401-411. (doi:10.1016/j.mcn.2006.08.009)
39. Felipe A, Soler C, Comes N. 2010 Kv1.5 in the immune system: the good, the bad, or the ugly? Front. Physiol. 1, 152. (doi:10.3389/fphys.2010.00152)
40. + channels in macrophages: molecular and biophysical consequences. J. Gen. Physiol. 135, 135-147. (doi:10.1085/jgp. 200910334)
41. Craner MJ, Damarjian TG, Liu S, Hains BC, Lo AC, Black JA, Newcombe J, Cuzner ML, Waxman SG. 2005 Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49, 220-229. (doi:10.1002/glia.20112)
42. Zsiros E, Kis-Toth K, Hajdu P, Gaspar R, Bielanska J, Felipe A, Rajnavolgyi E, Panyi G. 2009 Developmental switch of the expression of ion channels in human dendritic cells. J. Immunol. 183, 4483-4492. (doi:10.4049/jimmunol.0803003)
43. Kis-Toth K et al. 2011 Voltage-gated sodium channel Nav1.7 maintains the membrane potential and regulates the activation and chemokine-induced migration of a monocyte-derived dendritic cell subset. J. Immunol. 187, 1273-1280. (doi:10.4049/jimmunol.1003345)
44. Schlichter L, Sidell N, Hagiwara S. 1986 Potassium channels mediate killing by human natural killer cells. Proc. Natl Acad. Sci. USA 83, 451-455. (doi:10.1073/pnas.83.2.451)
45. Koshy S et al. 2013 Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS ONE 8, e76740. (doi:10.1371/journal.pone.0076740)
46. 2+-activated ion channels in human neutrophils. JClinInvest. 85, 491-498. (doi:10.1172/JCI114464)
47. + channel in effector memory T cells as new target for MS. J. Clin. Invest. 111, 1703-1713.
48. + channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J. Immunol. 173, 776-786.
49. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999 Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712. (doi:10.1038/44385)
50. + regulatory and naive T cells from healthy subjects and multiple sclerosis patients. Immunol. Lett. 124, 95-101. (doi:10.1016/j.imlet. 2009.04.008)
51. Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, Cahalan MD, Chandy KG. 2000 Upregulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J. Biol. Chem. 275, 37 137-37 149. (doi:10.1074/jbc.M003941200)
52. Varga Z, Hajdu P, Panyi G. 2010 Ion channels in T lymphocytes: an update on facts, mechanisms and therapeutic targeting in autoimmune diseases. Immunol. Lett. 130, 19-25. (doi:10.1016/j.imlet. 2009.12.015)
53. Beeton C, Pennington MW, Norton RS. 2011 Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm. Allergy Drug Targets 10, 313-321. (doi:10.2174/187152811797200641)
54. Chi V et al. 2012 Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon 59, 529-546. (doi:10.1016/j.toxicon.2011.07.016)
55. Varga Z et al. 2012 Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells. Mol. Pharmacol. 82, 372-382. (doi:10.1124/mol.112.078006)
56. Gurrola GB, Hernandez-Lopez RA, Rodriguez de la Vega RC, Varga Z, Batista CV, Salas-Castillo SP, Panyi G, del Rio-Portilla F, Possani LD. 2012 Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes. Biochemistry 51, 4049-4061. (doi:10.1021/bi300060n)
57. + channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem. J. 385, 95-104. (doi:10.1042/BJ20041379)
58. Castaneda O, Sotolongo V, Amor AM, Stocklin R, Anderson AJ, Harvey AL, Engstrom A, Wernstedt C, Karlsson E. 1995 Characterization of a potassium channel toxin from the Caribbean sea anemone Stichodactyla helianthus. Toxicon 33, 603-613. (doi:10.1016/0041-0101(95)00013-C)
59. Pennington MW et al. 1995 Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone. Int. J. Pept. Protein Res. 46, 354-358. (doi:10.1111/j.1399-3011.1995.tb01068.x)
60. Matheu MP et al. 2008 Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 29, 602-614. (doi:10.1016/j.immuni. 2008.07.015)
61. Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hansel W, Chandy KG. 2004 Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol. Pharmacol. 65, 1364-1374. (doi:10.1124/mol.65.6.1364)
62. Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hansel W, Wulff H. 2005 Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol. Pharmacol. 68, 1254-1270. (doi:10.1124/mol.105.015669)
63. Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H. 2007 Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J. Invest. Dermatol. 127, 1419-1429. (doi:10.1038/sj.jid. 5700717)
64. Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, Shakkottai V. 2007 Modulators of small-and intermediate-conductance calciumactivated potassium channels and their therapeutic indications. Curr. Med. Chem. 14, 1437-1457. (doi:10.2174/092986707780831186)
65. Wulff H, Castle NA. 2010 Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev. Clin. Pharmacol. 3, 385-396. (doi:10.1586/ecp.10.11)
66. + channels. J. Biol. Chem. 275, 1201-1208. (doi:10.1074/jbc.275.2.1201)
67. + channel, IKCa1: a potential immunosuppressant. Proc. Natl Acad. Sci. USA 97, 8151-8156. (doi:10.1073/pnas.97.14.8151)
68. Conforti L, Petrovic M, Mohammad D, Lee S, Ma Q, Barone S, Filipovich AH. 2003 Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes: a possible role in T cell proliferation. J. Immunol. 170, 695-702.
69. Chimote AA, Kuras Z, Conforti L. 2012 Disruption of kv1.3 channel forward vesicular trafficking by hypoxia in human T lymphocytes. J. Biol. Chem. 287, 2055-2067. (doi:10.1074/jbc.M111.274209)
70. Correale P et al. 2012 Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin. Cancer Res. 18, 850-857. (doi:10.1158/1078-0432.CCR-10-3186)
71. Hopken UE, Droese J, Li JP, Joergensen J, Breitfeld D, Zerwes HG, Lipp M. 2004 The chemokine receptor CCR7 controls lymph node-dependent cytotoxic T cell priming in alloimmune responses. Eur. J. Immunol. 34, 461-470. (doi:10.1002/eji. 200324690)
72. Zou W. 2006 Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307. (doi:10.1038/nri1806)
73. Ruter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. 2009 Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front. Biosci. 14, 1761-1770. (doi:10.2741/3338)
74. Oh-Hora M, Komatsu N, Pishyareh M, Feske S, Hori S, Taniguchi M, Rao A, Takayanagi H. 2013 Agonistselected T cell development requires strong T cell receptor signaling and store-operated calcium entry. Immunity 38, 881-895. (doi:10.1016/j.immuni. 2013.02.008)
75. Meyer C et al. 2011 Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl Acad. Sci. USA 108, 17 111-17 116. (doi:10.1073/pnas.1012530108)
76. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. 2012 Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268. (doi:10.1038/nri3175)
77. Gabrilovich DI, Nagaraj S. 2009 Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174. (doi:10.1038/nri2506)
78. Hegde VL, Nagarkatti PS, Nagarkatti M. 2011 Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. PLoS ONE 6, e18281. (doi:10.1371/journal.pone.0018281)
79. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M. 2004 Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br. J. Pharmacol. 143, 247-250. (doi:10.1038/sj.bjp.0705920)
80. Ramer R, Merkord J, Rohde H, Hinz B. 2010 Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem. Pharmacol. 79, 955-966. (doi:10.1016/j.bcp.2009.11.007)
81. Ames E, Murphy WJ. 2013 Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol. Immunother.
82. Morrison CJ, Butler GS, Rodriguez D, Overall CM. 2009 Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr. Opin. Cell Biol. 21, 645-653. (doi:10.1016/j.ceb.2009.06.006)
83. Page-McCaw A, Ewald AJ, Werb Z. 2007 Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8, 221-233. (doi:10.1038/nrm2125)
84. Rangaraju S et al. 2010 Potassium channel modulation by a toxin domain in matrix metalloprotease 23. J. Biol. Chem. 285, 9124-9136. (doi:10.1074/jbc.M109.071266)
85. Hegedus L, Cho H, Xie X, Eliceiri GL. 2008 Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J. Cell Physiol. 216, 480-485. (doi:10.1002/jcp.21417)
86. Nguyen HM, Galea CA, Schmunk G, Smith BJ, Edwards RA, Norton RS, Chandy KG. 2013 Intracellular trafficking of the KV1.3 potassium channel is regulated by the prodomain of a matrix metalloprotease. J. Biol. Chem. 288, 6451-6464. (doi:10.1074/jbc.M112.421495)
87. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl Acad. Sci. USA 102, 9571-9576. (doi:10.1073/pnas.0503726102)